Given the potential synergistic role of the EGFR-ZKSCAN3 signaling axis in the remodeling of the tumor microenvironment, the combined detection of the expression levels of the two may provide new biomarker combinations for the early diagnosis, prognostic assessment, and the design of targeted therapeutic strategies for ovarian cancer, with potential clinical translational value [92,93]. This evidence concerns the gene EGFR and ovarian carcinoma.